Aurinia Pharmaceuticals (AUP) Stock Price, News & Analysis

Company Overview

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 4.61 million shs
• Average Volume: 229,895 shs
• Market Capitalization: C$2.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AUP Stock Analysis - Frequently Asked Questions

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Neovasc (NVCN), NVIDIA (NVDA), Aurora Cannabis (ACB) and Aphria (APHA).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Computer and Technology
• Industry: Technical & System Software
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:AUP
• Previous Symbol: TSE:ISA
• CIK: N/A
• Web: www.auriniapharma.com
• Phone: +1-250-7084272
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 2.69
• Current Ratio: 11.93
• Quick Ratio: 11.02

Sales & Book Value

• Annual Sales: C$57.59 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 6.75
• Book Value: C$2.59 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 128,396,000
• Free Float: N/A
• Market Cap: C$2.15 billion
• Optionable: Not Optionable
• Beta: N/A